BioCentury | Oct 20, 2016
Product R&D

Chaperoning the DJ

In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in the...
Items per page:
1 - 1 of 1